CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve ...

The latest price target for Fulcrum Therapeutics (NASDAQ:FULC) was reported by Truist Securities on December 11, 2025. The analyst firm set a price target for $18.00 expecting FULC to rise to within ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Abstract: In robotic minimally invasive surgery, the incision point acts as a fulcrum around which the surgical instrument pivots. The fulcrum point has been the topic of much research. Mechanisms ...

Fulcrum Therapeutics (NASDAQ:FULC) fell ~10% on Tuesday after the company posted data from a late-stage study of its lead candidate, Pociredir, in sickle cell disease, along with second quarter ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

New roadmap introduces intelligent, hands-free operations powered by Agentic AI, setting a bold new standard for productivity, safety, and compliance in critical infrastructure industries San ...

Fulcrum’s Speed wheelset portfolio echoes the tenets of parent company Campagnolo, focussing on premium aesthetics and performance. The Speed range spans the 25, 42 and 57mm models and has been ...

Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end the ...

Fulcrum Digital has unveiled plans to scale its AI ecosystem to 10,000 AI agents by the end of 2025 as part of its enterprise AI innovation strategy. The announcement comes as the digital ...